Treatments received
| Details of treatments received . | Overall population . | Treatment subgroups . | P . | ||
|---|---|---|---|---|---|
| R(G)-ACVBP . | R(G)-CHOP14 . | R-CHOP21 . | |||
| Anti-CD20 monoclonal antibody | 313 (100%) | 180 (100%) | 76 (100%) | 57 (100%) | |
| Rituximab | 296 (94.6%) | 168 (93.3%) | 71 (93.4%) | 57 (100%) | <.001 |
| Obinutuzumab | 17 (5.4%) | 12 (6.7%) | 5 (6.6%) | 0 | |
| CNS prophylaxis | |||||
| Intrathecal methotrexate and/or HD MTX | 261 (83.4%) | 177 (98.3%) | 59 (77.6%) | 25 (43.9%) | <.001 |
| Intrathecal methotrexate | 229 (73.2%) | 148 (82.2%) | 58 (76.3%) | 23 (40.4%) | <.001 |
| HD MTX | 140 (44.7%) | 132 (73.3%) | 6 (7.9%) | 2 (3.5%) | <.001 |
| Consolidation ASCT | 71 (22.7%) | 46 (25.6%) | 24 (31.6%) | 1 (1.8%) | <.001 |
| CRT | 17 (5.4%) | 4 (2.2%) | 11 (14.5%) | 2 (3.5%) | <.001 |
| Consolidation ASCT + CRT | 8 (2.6%) | 3 (1.7%) | 5 (6.6%) | 0 (0%) | .043 |
| LYSA sequential consolidation chemotherapy (2× HD MTX, 4× R-IFM-VP16, 2× SC-CYTA) | 128 (41%) | 128 (71.1%) | — | — | |
| Patients who have completed 6-8 cycles of R(G)-CHOP | 95 (30.4%) | — | 44 (57.9%) | 51 (89.5%) | |
| Details of treatments received . | Overall population . | Treatment subgroups . | P . | ||
|---|---|---|---|---|---|
| R(G)-ACVBP . | R(G)-CHOP14 . | R-CHOP21 . | |||
| Anti-CD20 monoclonal antibody | 313 (100%) | 180 (100%) | 76 (100%) | 57 (100%) | |
| Rituximab | 296 (94.6%) | 168 (93.3%) | 71 (93.4%) | 57 (100%) | <.001 |
| Obinutuzumab | 17 (5.4%) | 12 (6.7%) | 5 (6.6%) | 0 | |
| CNS prophylaxis | |||||
| Intrathecal methotrexate and/or HD MTX | 261 (83.4%) | 177 (98.3%) | 59 (77.6%) | 25 (43.9%) | <.001 |
| Intrathecal methotrexate | 229 (73.2%) | 148 (82.2%) | 58 (76.3%) | 23 (40.4%) | <.001 |
| HD MTX | 140 (44.7%) | 132 (73.3%) | 6 (7.9%) | 2 (3.5%) | <.001 |
| Consolidation ASCT | 71 (22.7%) | 46 (25.6%) | 24 (31.6%) | 1 (1.8%) | <.001 |
| CRT | 17 (5.4%) | 4 (2.2%) | 11 (14.5%) | 2 (3.5%) | <.001 |
| Consolidation ASCT + CRT | 8 (2.6%) | 3 (1.7%) | 5 (6.6%) | 0 (0%) | .043 |
| LYSA sequential consolidation chemotherapy (2× HD MTX, 4× R-IFM-VP16, 2× SC-CYTA) | 128 (41%) | 128 (71.1%) | — | — | |
| Patients who have completed 6-8 cycles of R(G)-CHOP | 95 (30.4%) | — | 44 (57.9%) | 51 (89.5%) | |
etoposide, cytarabine, and melphalan; G, obinutuzumab; HD MTX, high-dose methotrexate 3 g/m2; R-IFM, rituximab and ifosfamide; SC-CYTA, subcutaneous cytarabine; VP16, etoposide; CRT, consolidation radiation therapy; R, rituximab; G, obinutuzumab; ASCT, autologous stem cell transplant; CNS, central nervous system.